Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT05295017

LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults (LEV93A)

Status
Active Not Recruiting
Phase
Study type
Observational
Enrollment
1,235 (actual)
Sponsor
Elypta · Industry
Sex
All
Age
55 Years – 80 Years
Healthy volunteers
Accepted

Summary

LEVANTIS-0093A (LEV93A) is a prospective cohort observational clinical study to validate the plasma free GAGome MCED test in adults at high risk of developing cancer ("high-risk adults"), specifically in 55-80-year-old adults with significant smoking history. LEV93A will use plasma biospecimens collected within the Yorkshire Lung Screening Trial Biomarker sub-study and corresponding participant data prospectively collected within the Yorkshire Lung Screening Trial (YLST) and the Yorkshire Kidney Screening Trial (YKST) all of which are sponsored by the University of Leeds and funded by Yorkshire Cancer Research (Award references: L403, L403B L403C), in collaboration with the University of Leeds, with the University of Manchester and with the Leeds Teaching Hospitals.

Conditions

Timeline

Start date
2022-03-14
Primary completion
2025-10-01
Completion
2026-03-01
First posted
2022-03-24
Last updated
2024-09-19

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05295017. Inclusion in this directory is not an endorsement.